Vistagen Therapeutics (VTGN) Net Equity Issued and Repurchased (2011 - 2026)

Vistagen Therapeutics has reported Net Equity Issued and Repurchased for 16 years, with the latest figure at -$30.6 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 2795.09% year-over-year to -$30.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33000.0 (down 178.57% YoY) and the FY2026 annual result came in at $8000.0, changed N/A from the prior year.
• Net Equity Issued and Repurchased retreated to -$30.6 million in Q1 2026 per VTGN's latest filing, from $2.3 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $57.2 million in Q1 2024 and troughed at -$30.6 million in Q1 2026.
• A 5-year average of $6.7 million and a median of $327950.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2023 and 2026: Net Equity Issued and Repurchased surged 116325.17% in 2023, then sank 2795.09% in 2026.
• Over 5 years, Net Equity Issued and Repurchased stood at $89600.0 in 2022, then soared by 134.38% to $210000.0 in 2023, then surged by 423.81% to $1.1 million in 2024, then jumped by 109.09% to $2.3 million in 2025, then tumbled by 1431.74% to -$30.6 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$30.6 million, $2.3 million, and $27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.